Ayako Shoji
Papers
1
Total Citations
35
H-Index
1
About
Dr. Ayako Shoji is a distinguished researcher in oncology and biomarker discovery, with a primary focus on improving treatment outcomes for pancreatic cancer patients. Her most-cited work, a 2010 study on survival prediction for pancreatic cancer patients receiving gemcitabine treatment, has garnered 35 citations and addresses a critical clinical challenge: the variability in patient response to standard gemcitabine monotherapy. Dr. Shoji’s major contribution lies in identifying new biomarkers predictive of overall survival, employing advanced liquid chromatography-mass spectrometry (LC-MS) to analyze baseline patient samples. This research aims to personalize treatment strategies, sparing non-responders from ineffective therapy and guiding more targeted interventions. Her work has significant implications for precision oncology, helping to refine prognostic models in a disease with notoriously poor outcomes. By bridging molecular profiling and clinical decision-making, Dr. Shoji’s achievements underscore her commitment to translating laboratory discoveries into tangible benefits for patients, making her a notable figure in the fight against pancreatic cancer.
Research Focus
Key Achievements
Top Papers
- 1